Research progress of Parkinson syndrome associated with trimetazidine
10.3760/cma.j.cn114015-20200515-00529
- VernacularTitle:曲美他嗪相关帕金森综合征研究进展
- Author:
Leilei MEI
1
;
Feng REN
;
Weifang ZHANG
;
Lei XIONG
;
Wuping ZHANG
;
Ye LIU
Author Information
1. 南昌大学第二附属医院药学部，南昌 330006
- Publication Type:Journal Article
- Keywords:
Trimetazidine;
Parkinson disease, secondary
- From:
Adverse Drug Reactions Journal
2020;22(12):689-692
- CountryChina
- Language:Chinese
-
Abstract:
Trimetazidine (TMZ) is a drug that could optimize myocardial energy metabolism and is widely used in the prophylactic treatment of angina pectoris. TMZ-associated Parkinson syndrome accounted for 1.9% (3/155) of drug-induced Parkinson syndrome and 8.4% (161/1 916) of TMZ-related adverse events. The estimated incidence was 0.36/100 000 patient-years. TMZ-associated Parkinson syndrome can occur from 1 month to 7 years after taking the medicine and mainly in 9 to 15 months; its clinical manifestation is similar to that of primary Parkinson disease, but the treatments for them are quite different. Therefore, attention should be paid to the differentiation. Age ≥65 years and combination with stroke are risk factors for TMZ-associated Parkinson syndrome. Patients diagnosed with TMZ-associated Parkinson syndrome should discontinue TMZ immediately and should be forbidden from using the drug for life. The symptoms in most patients can completely disappear or significantly be improved after discontinuation of TMZ and for a few patients with persistent symptoms, dopamine supplements such as levodopa and benserazide hydrochloride tablets could be given appropriately. TMZ is contraindicated in patients who have been diagnosed with Parkinson disease. The mechanism of TMZ-induced Parkinson syndrome may be related to the piperazine core structure, which has the effect of blocking dopamine receptors.
